

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
05 March 2020 (05.03.2020)



(10) International Publication Number
WO 2020/043878 A1

(51) International Patent Classification:

A61K 31/635 (2006.01) *A61K 47/68* (2017.01)
A61K 45/06 (2006.01) *A61P 35/00* (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2019/073212

(22) International Filing Date:

30 August 2019 (30.08.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1814207.5 31 August 2018 (31.08.2018) GB
1908225.4 10 June 2019 (10.06.2019) GB

(71) Applicants: **ADC THERAPEUTICS SA** [CH/CH];
Biopôle route de la Corniche 3b, 1066 Epalinges (CH).
MEDIMMUNE LIMITED [GB/GB]; Milstein Building,
Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(72) Inventors: **ZAMMARCHI, Francesca**; c/o ADC Therapeutics SA, Biopôle route de la Corniche 3b, 1066 Epalinges (CH). **BERTONI, Francesco**; c/o IOR Istituto Oncologico di Ricerca, Fondazione per la ricerca e la cura dei Linfomi in Ticino, Via Vincenzo Vela 6, 6500 Bellinzona (CH).

(74) Agent: **MEWBURN ELLIS LLP**; City Tower, 40 Basinghall Street, London Greater London EC2V 5DE (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- of inventorship (Rule 4.17(iv))

(54) Title: COMBINATION THERAPY

(57) Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an anti-CD19 Antibody Drug Conjugate (anti-CD19 ADC) and an anti-BCL-2 agent.

WO 2020/043878 A1